Altimmune ALT 深 沪
等待开盘 06-25 09:30:00 美东时间
2.95
+0.040
+1.37%
华盛通- 最 高3.04
- 今 开2.92
- 成交量 349.41万股
- 最 低 2.92
- 昨 收 2.91
- 总市值 5.74亿
- 52周最高 6.4399
- 市盈率 静 --
- 换手率 1.80%
- 52周最低 2.56
- 委 比 -79.59%
- 总股本 1.94亿
- 历史最高 237.30
- 量 比 0.62
- 振 幅 4.12%
- 历史最低 1.51
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10
Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperform rating and announces Price Target of $10.
06-22 22:41
Altimmune Relocates Corporate Headquarters to Morristown, New Jersey
The latest announcement is out from Altimmune ( ($ALT) ). On June 16, 2026, Alt...
06-17 04:47
GLP-1 sales forecast increased to $150B at TD Cowen
GLP-1 drugs, the treatment class popularized by Eli Lilly (LLY) and Novo Nordisk (NVO), could generate $150B in global sales by the end of this decade, TD Cowen estimates, indicating a roughly ~8% inc...
06-05 22:22
Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis.
The data are being presented today and Friday in poster sessions, including a late-breaking poster presentation, at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain.
05-27 20:03
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Altimmune, Inc. announced that new analyses from the IMPACT Phase 2b trial show pemvidutide, a dual receptor agonist, significantly improves multiple non-invasive tests (NITs) for MASH activity and fibrosis at 24 weeks. Results demonstrate concurrent improvements in liver fat content, ALT, liver stiffness, and ELF scores, with 37.8% and 22.7% of patients on 1.2 mg and 1.8 mg doses achieving greater than 0.5 ELF reduction and greater than 30% LSM ...
05-27 12:00
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology May 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Costco Wholesale, HCA Healthcare and Micron Technology, on Tuesday. HIGHLIGHTS * Costco Who
05-19 15:56
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Altimmune Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Altimmune (NASDAQ:ALT) discussed first-quarter financial results ...
05-13 21:44
